ADT works by lowering levels of the potent AR ligands testosterone and dihydrotestosterone (DHT) or interfering with binding of androgen ligands to the androgen receptor (AR) protein, the principal therapeutic target in prostate cancer [2]. Here, AR is linked to Familial prostate cancer.